Nigerian-German Chemicals Valuation
Is NIG-GERMAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NIG-GERMAN?
Other financial metrics that can be useful for relative valuation.
|What is NIG-GERMAN's n/a Ratio?|
Price to Book Ratio vs Peers
How does NIG-GERMAN's PB Ratio compare to its peers?
|Company||PB||Estimated Growth||Market Cap|
NEIMETH Neimeth International Pharmaceuticals
MAYBAKER May & Baker Nigeria
GLAXOSMITH GlaxoSmithKline Consumer Nigeria
FIDSON Fidson Healthcare
NIG-GERMAN Nigerian-German Chemicals
Price-To-Book vs Peers: Insufficient data to calculate NIG-GERMAN's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Earnings Ratio vs Industry
How does NIG-GERMAN's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?
Price to Book Ratio vs Fair Ratio
What is NIG-GERMAN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||n/a|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate NIG-GERMAN's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of NIG-GERMAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NIG-GERMAN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NIG-GERMAN's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
- Take a look at our analysis of NIG-GERMAN's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Potentially undervalued companies in the Pharmaceuticals & Biotech industry.